Stem Cell Therapy for Multiple Sclerosis: Clinical Study Results

Published 27 May 2026

3 min read

Updated 27 May 2026

Mesenchymal stromal cells (MSCs) are being actively investigated for their immunomodulatory, anti-inflammatory, and neuroprotective properties, and there is a growing interest in their potential to support neurological function and improve quality of life in people living with MS.

We are glad to share the results of our internal research study on the safety and effectiveness of stem cell therapy for people with Multiple Sclerosis (MS). The study was conducted at the request of and in the interest of patients and was led by Dr. Lana Babinski, a specialist in regenerative medicine at Swiss Medica.

About the Research Study

The study conducted during 2025 involved 16 participants diagnosed with relapsing-remitting, secondary progressive, or primary progressive MS, aged between 30 and 65 years.

The treatment protocol included:

intravenous infusions of cultivated allogeneic mesenchymal stromal cells (MSCs),
intrathecal injections of autologous bone marrow mononuclear cells,
and a five-week course of MSC-derived exosomes administered via nasal drops.

Participants underwent baseline evaluations before treatment and follow-up assessments within 3 to 9 months after therapy.

The Key Findings

The stem cell treatment protocol was safe and well tolerated, with no serious adverse events reported during the observation period.

Among the mild to moderate adverse events observed, the most common were fever, chills, headache after intrathecal injection, and temporary elevation of D-dimer levels. No infusion-related infections or long-term treatment-related complications were identified.

The follow-up assessment period demonstrated encouraging clinical improvements across multiple symptom groups:

1
Walking and Balance

Following treatment, 40% demonstrated visible improvement, while another 40% experienced stabilization of their condition.
2
Muscle Tone and Motor Function

Among participants with impaired muscle tone, 53.3% demonstrated improvement after treatment, while 26.7% experienced stabilization of their condition.
3
Fatigue and Constitutional Symptoms

Among participants suffering from fatigue, dizziness, and sleep disturbances, 64.3% showed improvement, while 28.6% noted stabilization of symptoms.
4
Sensory Symptoms

Participants reported improvements or stabilization in symptoms such as numbness, paresthesias, neuropathic pain, and impaired sensation.

Overall, 68.8% of participants demonstrated significant improvement in at least one symptom, while 43.8% experienced improvement in half or more of their symptoms. In many participants, symptom progression also appeared to stabilize during the observation period.

A New Direction in MS Management

Since MS is a chronic neurodegenerative and autoimmune condition with no known cure, our objective was not to completely eliminate all symptoms of the disease. However, the results of this study suggest that combined MSC-based therapy may represent a safe and promising therapeutic approach for improving functional outcomes and quality of life in people living with MS.

Given the encouraging outcomes observed during this study, we recommend continuing to use this treatment protocol for patients with MS while pursuing further clinical research and long-term follow-up.

Get the Full Study

For those who would like to explore the complete study and detailed results, we invite you to request the full report by leaving your email address below.